Top Markets
Coin of the day
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd.

TARO
Classifica tra le azioni #7354
Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven... Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven pharmaceutical enterprise, specializing in the development, manufacturing, and commercialization of both prescription and over-the-counter medications. Its market reach spans the United States, Canada, Israel, and various other international territories. The company also produces active pharmaceutical ingredients (APIs), primarily for integration into its own finished dosage form products. Its extensive product catalog addresses a broad spectrum of medical conditions and therapeutic areas, encompassing treatments for allergies, pain (analgesic), bacterial and fungal infections (antibacterial, antibiotic, antifungal), seizures (anticonvulsant), nausea (antiemetic), inflammation (anti-inflammatory), cancer (anti-cancer, topical anti-neoplastic), blood clot prevention (antiplatelet agent), fever reduction (antipyretic), cardiovascular issues, central nervous system disorders, hormonal regulation (corticosteroid, endocrine), cosmetic applications, coughs and colds, dermatological complaints, fluid management (diuretic), gastrointestinal problems, constipation (laxative), severe pain (narcotics), neuropathic pain, neuropsychiatric conditions, and sleep/anxiety management (sedative/hypnotic). These pharmaceutical goods are available in numerous formats, including capsules, creams, drops, emulsions, gels (and gel kits), granules, injectables, lotions, oils, ointments, pastes, powders (and powders for solution), rectal suppositories, shampoos, solutions (and solutions for infusion), sprays, suspensions, syrups, tablets, toothpastes and mouthwashes, topical foams, and topical solutions. Taro distributes and sells its products directly to a wide array of clients, such as pharmaceutical wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, other direct purchasers, and various healthcare institutions and private pharmacies. The company was established in 1950, with its main offices situated in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a wholly-owned subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
Prezzo delle azioni
$42.98
Ultima sincronizzazione: 2024-06-21
Capitalizzazione di mercato
$1.62B
Variazione (1 giorno)
0.01%
Variazione (1 anno)
0.00%
Paese
IL
Scambia Taro Pharmaceutical Industries Ltd. (TARO)

Categoria

Rapporto P/E per Taro Pharmaceutical Industries Ltd. (TARO)
Rapporto P/E al August 2026 TTM: 30.05
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Taro Pharmaceutical Industries Ltd., il rapporto P/E attuale (TTM) è 30.05. Alla fine del 2023, il rapporto P/E era 35.92.
Storico del rapporto P/E per Taro Pharmaceutical Industries Ltd. da 1999 a 2026
Rapporto P/E alla fine di ogni anno
Anno Rapporto P/E Cambia
2026 (TTM) 30.05 1.98%
2024 29.47 -17.98%
2023 35.92 28.54%
2022 27.95 -497.43%
2021 -7.03 -172.97%
2020 9.64 -36.03%
2019 15.07 -19.08%
2018 18.62 76.40%
2017 10.55 -6.95%
2016 11.34 -9.07%
2015 12.47 -8.53%
2014 13.64 38.57%
2013 9.84 52.53%
2011 6.45 -29.15%
2010 9.11 198.06%
2009 3.06 -69.11%
2008 9.89 27.00%
2007 7.79 -319.39%
2006 -3.55 -104.93%
2005 71.98 -19.62%
2004 89.55 194.34%
2003 30.42 25.42%
2002 24.26 -32.60%
2001 35.99 8.92%
2000 33.04 25.29%
1999 26.38 0.00%
Rapporto P/E per aziende simili o concorrenti
Come leggere un P/E ratio?

Il rapporto Prezzo/Utile (P/E) misura la relazione tra il prezzo delle azioni di una società e i suoi utili per azione.
Un P/E basso ma positivo indica un'azienda che genera alti profitti rispetto alla sua valutazione attuale e potrebbe essere sottovalutata. Un'azienda con un P/E negativo elevato (vicino allo 0) segnala forti perdite rispetto alla valutazione.

Le aziende con un P/E superiore a 30 o negativo sono generalmente considerate "azioni di crescita", cioè ci si aspetta che crescano o diventino redditizie.

Le aziende con un P/E positivo inferiore a 10 sono considerate "azioni di valore", ossia già molto redditizie ma con scarse prospettive di crescita.